Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

Is Exemestane More Effective Than Tamoxifen in Reducing Recurrence After Early-Stage Breast Cancer Treatment?

Is Exemestane More Effective Than Tamoxifen in Reducing Recurrence After Early-Stage Breast Cancer Treatment?

According to a recently published study in the British medical journal “New England Journal of Medicine,” exemestane was more effective than tamoxifen in preventing recurrence after early-stage breast cancer treatment.

Breast cancer is the most common cancer in women. Lifetime risk is approximately %12, meaning one in every 8 women will develop it. Prevention and early diagnosis are priorities, but effective treatment and prevention of recurrence are equally important. Disease returning when a patient believes she has recovered is devastating for her and her family. Surgery to remove the tumor is currently commonly used for early-stage cancer, followed by recurrence-prevention strategies.

In early-stage hormone receptor-positive breast cancer, ovarian suppression to reduce the estrogen source and additional protective treatment (adjuvant therapy) with tamoxifen prevent recurrence. ‘Hormone receptor-positive’ means cancer cells are estrogen-sensitive and estrogen contributes to development. Suppressing it is therefore effective. Tamoxifen is conventionally used to prevent recurrence after treatment, but a recently published comprehensive study found exemestane more effective.

Among approximately 4700 premenopausal women with early-stage breast cancer, around 2350 received exemestane and 2350 tamoxifen. Both groups also received ovarian-suppressing medication to prevent unwanted effects and were followed for 68 months. Analysis found more disease-free patients, fewer recurrences and higher 5-year survival with exemestane. Bone and joint pain, vaginal dryness and reduced sexual desire were more frequent with exemestane; hot flashes and vaginal discharge were more frequent with tamoxifen. Overall quality of life did not differ substantially.

In conclusion, adjuvant exemestane is progressing toward becoming a new, effective option for preventing recurrence in premenopausal women with early-stage hormone receptor-positive breast cancer. More studies are nevertheless needed before it becomes standard treatment.

Sources

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

Is Exemestane More Effective Than Tamoxifen in Reducing Recurrence After Early-Stage Breast Cancer Treatment?

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy